Press Releases

Date Title
November 19, 2020
Outlook Therapeutics Announces Creation of Global Retina Advisory Council
Advisory Co uncil to collaborate on ou t reach to retinal clinicians to support development and commercialization of ONS-5010, an investigational ophthalmic formulation of bevac i zumab MONMOUTH JUNCTION, N.J. , Nov. 19, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.
November 11, 2020
Virtual KOL Roundtable Recap: Outlook Therapeutics and Firas Rahhal, MD, Discussed wet AMD Treatment Landscape and ONS-5010/LYTENAVA™
Dr. Rahhal , a leading retinal clinician,   offer ed   insight on wet AMD treatment and the p otential of ONS-5010/ LYTENA VA ™ (bevacizumab-vikg) , if approved, to improve available treatment options Outlook Therapeutics detail ed   ongoing development and pre- commercial planning of ONS-5010/
November 5, 2020
Outlook Therapeutics Secures $10 Million in Additional Working Capital
MONMOUTH JUNCTION, N.J. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced the issuance of
November 3, 2020
Outlook Therapeutics Completes Patient Enrollment of Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Full enrollment of 195   subjects in NORSE THREE achieved in less than one month, significantly ahead of schedule All planned clinical trials for ONS-5010/LYTENAVA ™ BLA for wet AMD now fully enrolled or completed Pivotal data expected in mid-2021 from ongoing, fully enrolled Phase 3 registration
October 22, 2020
Outlook Therapeutics to Present at the Virtual Investor KOL Roundtable
Live moderated video webcast discussion among members of management and Key Opinion Leader Firas M. Rahhal, MD on Thursday, October 29th at 10:00 AM ET MONMOUTH JUNCTION, N.J. , Oct. 22, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical
October 13, 2020
Outlook Therapeutics Announces Initiation of Supplemental Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
First subjects have been enrolled in supplemental open-label safety study S tudy being conducted t o ensure the requisite number of patient exposures to ONS-5010 to support   new BLA filing to the FDA in 2021 ONS-5010 , an investigational ophthalmic formulation of bevacizumab- vikg for the
October 7, 2020
Outlook Therapeutics to Present at the Virtual BIO Investor Forum Digital
MONMOUTH JUNCTION, N.J. , Oct. 07, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence
September 30, 2020
Outlook Therapeutics Provides Update on Progress Towards First Approved Ophthalmic Formulation of Bevacizumab-vikg for Advanced Macular Degeneration
MONMOUTH JUNCTION, N.J. , Sept. 30, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) is a late clinical-stage biopharmaceutical company developing the first FDA-approved ophthalmic formulation of bevacizumab-vikg (LYTENAVA™) for use in retinal indications (known as ONS-5010).
September 8, 2020
Outlook Therapeutics to Present at Two Upcoming Investor Conferences
MONMOUTH JUNCTION, N.J. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence
August 26, 2020
Outlook Therapeutics Reports Topline Results and Positive Proof-of-Concept for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) from NORSE 1
ONS-5010, an investigational ophthalmic formulation of bevacizumab-vikg for the treatment of wet AMD, demonstrated safety and efficacy profile consistent with previously published ophthalmic bevacizumab research NORSE 1 results support trial design and inclusion criteria for fully enrolled, ongoing
Displaying 1 - 10 of 100